BioInvest In The News

MarketWatch (2-26-15)
Forbes (2-25-15)
The Money Show (2-25-15)
MoneyShow Five Prime (1-19-15)
Life Sciences Report (12-30-14)
Dash of Insight (11-16-14)
Company Updates
Pharmacyclics Update (2-26-15)

Pharmacyclics Update (2-26-15)

 Special Update BioInvest News for PCYC  – Buyout Rumor Lifts Cancer Stocks – Bloomberg’s report today that Pharmacyclics is in play with partner JNJ and Novartis leading the potential bidders sent PCYC stock up 16%.  The story almost immediately lifted the stocks of a slew of biotech names that are developing cancer drugs, as traders quickly pounced on [...]

Pharmacyclics Update (2-25-15)

Pharmacyclics Update (2-25-15)

Special Update BioInvest News for PCYC  – Comments On The JNJ/NVS Acquisition Article On Bloomberg – For a long time, our view was that Imbruvica was a blockbuster drug, may be the best selling cancer drug ever, and its future continues to get brighter. With $1 billion in U.S. sales alone predicted for its second year on [...]

Anthera Update (2-10-15)

Anthera Update (2-10-15)

ANTH – B-Mod Passes Futility Analysis, Signaling A Signal – REITERATE BUY – Anthera announced a successful interim look of the CHABLIS-SC1 Phase 3 trial of blisibimod in patients with Systemic Lupus Erythematosus (SLE) and that the study should continue to completion as planned. An independent statistician conducted the interim futility analysis for the CHABLIS-SC1 [...]